No Data
No Data
MannKind Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
MannKind's Earnings Call Highlights Robust Growth and Strategic Success
Wells Fargo Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $9
Wedbush Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $11
Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), MannKind (MNKD)
Wells Fargo Sticks to Its Buy Rating for MannKind (MNKD)
Stock_Drift OP : $MannKind (MNKD.US)$
下一个十年的雷熊 : Seems favorable. Strange, there isn't much movement ahead of the market![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)